Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Barbara Pistilli, Angelo Paci, Arlindo R Ferreira, Antonio Di Meglio, Vianney Poinsignon, Aurelie Bardet, Gwenn Menvielle, Agnes Dumas, Sandrine Pinto, Sarah Dauchy, Leonor Fasse, Paul H Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Olivier Tredan, Patrick Soulie, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Sibille Everhard, Patrick Arveux, Anne Laure Martin, Alexandra Dima, Nancy U Lin, Ann H Partridge, Suzette Delaloge, Stefan Michiels, Fabrice André, Ines Vaz-Luis, Barbara Pistilli, Angelo Paci, Arlindo R Ferreira, Antonio Di Meglio, Vianney Poinsignon, Aurelie Bardet, Gwenn Menvielle, Agnes Dumas, Sandrine Pinto, Sarah Dauchy, Leonor Fasse, Paul H Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Olivier Tredan, Patrick Soulie, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Sibille Everhard, Patrick Arveux, Anne Laure Martin, Alexandra Dima, Nancy U Lin, Ann H Partridge, Suzette Delaloge, Stefan Michiels, Fabrice André, Ines Vaz-Luis

Abstract

Purpose: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS).

Patients and methods: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size.

Results: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort.

Conclusion: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.

Figures

FIG 1.
FIG 1.
CONSORT diagram of study participants. AI, aromatase inhibitor; ET, endocrine therapy; HR, hormone receptor; LHRH, luteinizing hormone-releasing hormone; TAM, tamoxifen.
FIG 2.
FIG 2.
Multivariate estimates of variables associated with serum-defined adherence. Severe fatigue and insomnia were defined as the respective subscale European Organization for Research and Treatment of Cancer–C30 score > 40. Anxiety and depression were defined using the Hospital Anxiety and Depression Scale. BMI, body mass index; CT, chemotherapy; OR odds ratio.
FIG 3.
FIG 3.
Distant disease-free survival (DDFS; distant recurrences and death) according to serum-defined adherence status in (A) the IPTW cohort and in the (B) non-IPTW cohort. Time 0 defines the time of the post-tamoxifen prescription visit and date of serum assessment of tamoxifen. HR, hazard ratio; IPTW, inverse probability treatment weighting.

References

    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
    1. Sabaté E (ed): Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland, World Health Organization, 2003.
    1. Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018;320:2461–2473.
    1. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–1197.
    1. Rosenbaum L, Shrank WH. Taking our medicine--Improving adherence in the accountability era. N Engl J Med. 2013;369:694–695.
    1. Lu CY, Zhang F, Wagner AK, et al. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. Breast Cancer Res Treat. 2018;171:235–242.
    1. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: A summary of the literature. Med Care. 2004;42:649–652.
    1. Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation of endocrine treatment in breast cancer: Methodological aspects. BMC Cancer. 2012;12:474.
    1. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
    1. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–606.
    1. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–4128.
    1. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484.
    1. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37:423–438.
    1. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34:3308–3314.
    1. Vaz-Luis I, Cottu P, Mesleard C, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) ESMO Open. 2019;4:e000562.
    1. Helmy R, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP Medication Adherence Reporting Guidelines (EMERGE): A reactive-Delphi study protocol. BMJ Open. 2017;7:e013496.
    1. Teunissen SF, Jager NG, Rosing H, et al. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:1677–1685.
    1. MacCallum J, Cummings J, Dixon JM, et al. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer. 2000;82:1629–1635.
    1. Highlights of prescribing information. Soltamox (tamoxifen citrate)
    1. Saladores P, Mürdter T, Eccles D, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15:84–94.
    1. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718–725.
    1. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–1764.
    1. Binkhorst L, van Gelder T, Loos WJ, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther. 2012;92:62–67.
    1. Hussaarts KGAM, Hurkmans DP, Oomen-de Hoop E, et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel) 2019;11:403.
    1. Lien EA, Anker G, Lønning PE, et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990;50:5851–5857.
    1. Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) Ann Oncol. 2015;26:873–879.
    1. Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35:5642–5655.
    1. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242–1258.
    1. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469–1476.
    1. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562.
    1. Sanchez-Spitman A, Dezentjé V, Swen J, et al. Tamoxifen pharmacogenetics and metabolism: Results from the prospective CYPTAM Study. J Clin Oncol. 2019;37:636–646.
    1. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–537.
    1. McCowan C, Wang S, Thompson AM, et al. The value of high adherence to tamoxifen in women with breast cancer: A community-based cohort study. Br J Cancer. 2013;109:1172–1180.
    1. Barron TI, Cahir C, Sharp L, et al. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer. 2013;109:1513–1521.
    1. Rae JM, Sikora MJ, Henry NL, et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009;9:258–264.
    1. McCorkle R, Ercolano E, Lazenby M, et al. Self-management: Enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin. 2011;61:50–62.
    1. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267–277.
    1. Abrahams HJ, Gielissen MF, Schmits IC, et al. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: A meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016;27:965–974.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever